In addition, the G12D and G12V mutations were associated with poor therapeutic outcomes in BTC patients who received GCD therapy, suggesting that KRAS variants may predict reduced efficacy of cancer immunotherapy regimens, including ICIs. The gene discussed is KRAS; the disease is cancer.